Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), operating as Movano Health, is a health-focused technology company dedicated to revolutionizing the way we manage and monitor our health metrics. Founded in 2018 and headquartered in Pleasanton, California, Movano is committed to developing healthcare solutions that bring medical-grade, high-quality data to consumer health devices. The company's flagship product, the Evie Ring, is a wearable designed specifically for women to track a comprehensive array of health metrics including resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, and skin temperature variability. It also monitors period and ovulation tracking, menstrual symptom tracking, steps, active minutes, calories burned, sleep stages and duration, and mood tracking.
Movano Health has made significant strides in advancing its Evie Ring technology, as evidenced by a recent hypoxia trial conducted in collaboration with the University of California, San Francisco (UCSF). The study confirmed that the accuracy of Evie's pulse oximeter exceeds FDA guidelines. This milestone underscores the company's objective to achieve FDA clearance for the Evie Med Ring, a medical-grade version of the wearable. The Evie Med Ring aims to provide a seamless blend of accessibility, personalization, and medical reliability, significantly differentiating itself from existing wellness solutions.
In addition to its technological advancements, Movano Health recently secured a strategic investment from a tier-one multi-billion dollar medical device company. This partnership, along with a $24 million capital raise, ensures financial stability and accelerates the commercialization of Movano's proprietary technologies. The company has also entered into agreements to explore future collaborations for the development and commercialization of their healthcare solutions.
Movano Health's commitment to innovation extends to strategic collaborations with prestigious institutions like MIT. The company’s Evie Ring is being utilized in the MAESTRO study to understand long COVID and chronic Lyme disease, providing continuous, reliable data that could reshape approaches to these debilitating conditions.
For more information on Movano Health and their latest updates, visit here.
Movano Inc. (NASDAQ: MOVE) will report its fourth-quarter 2022 financial results on March 20, 2023. The management will host a conference call at 9:00 a.m. PDT to discuss the results and provide a business update. The Evie Ring, aimed at women's health, is set to launch mid-2023. Movano focuses on providing medical-grade health data through consumer devices, enhancing the management of health for individuals and healthcare professionals. The company emphasizes the importance of personalized health insights, which will be integral for effective health management.
Movano Health, a healthcare solutions firm, announced on February 6, 2023, the completion of a $7.5 million public offering of 5,340,600 shares of common stock and warrants for 2,670,300 shares. The offering price was $1.40 per share, with warrants exercisable at $1.57. All securities were sold by Movano, and the net proceeds will support general corporate purposes like product development. Newbridge Securities Corporation acted as the underwriter. This offering is pivotal as Movano readies the launch of its health device, the Evie Ring, aimed at women's health, which is expected to be available in mid-2023.
Movano Health (Nasdaq: MOVE) has priced a $6.5 million underwritten public offering involving 4,644,000 shares of common stock and warrants for 2,322,000 shares. Each share and warrant is priced at $1.40 and $1.57 respectively, with the offering expected to close on January 31, 2023. The company plans to use the proceeds for general corporate purposes, including product development and commercialization. Newbridge Securities Corporation is the sole book-running manager for this offering, which may have a 30-day option for the underwriter to purchase an additional 15% of the offering.
Movano Health (Nasdaq: MOVE) announced a proposed underwritten public offering of shares and warrants to purchase common stock. The offering will be conducted by the company, which aims to grant the underwriter a 30-day option for an additional 15% of shares. Proceeds will support general corporate purposes, including product development and commercialization. Newbridge Securities Corporation is the sole book-running manager for the offering. The final terms are subject to market conditions, and the offering will be registered with the SEC. The company cautions that actual results may vary due to inherent risks and uncertainties.
Movano Health (Nasdaq: MOVE) plans to file for FDA clearance for its new women-focused wearable, the Evie smart ring, which integrates medical-grade health data into a user-friendly mobile app. Designed to enhance women's health insights, Evie will provide metrics including heart rate, SpO2, and menstrual tracking, aiming to empower users to make informed health decisions without a subscription fee. Following a successful hypoxia trial confirming accuracy, Evie is set to debut at CES 2023, priced below $300 and available in 2023.
Movano Health (NASDAQ: MOVE) announced promising preliminary results from its pivotal hypoxia trial, demonstrating a 2% margin of error for blood oxygen saturation (SpO2) and a heart rate error of 2 BPM. Both metrics exceeded FDA standards, indicating high accuracy. The trial involved 11 subjects and followed an FDA-required protocol. Movano plans to file for FDA clearance in 2023. CEO John Mastrototaro emphasized the importance of developing wearable devices that empower consumers with reliable health data.
Movano Health has initiated a beta program for its smart ring, designed to track and analyze medical-grade data, in collaboration with Novant Health. Approximately 30 team members from Novant will assess the smart ring's functionality and wearability. The beta program, set to commence this month, aims to prepare Movano for its product launch targeted for the first half of 2023. The collaboration underscores a shared goal of making healthcare more accessible and could provide vital feedback for Movano's technology development in consumer health.
Movano Health (Nasdaq: MOVE) announced participation in several investor-focused events to discuss progress on its smart ring and an integrated circuit for blood pressure and glucose monitoring. Upcoming events include the Bernstein CGM Disruptors Conference on November 18, 2022, the BTIG Digital Health Forum on November 21, 2022, and the Benchmark Discovery Conference on December 1, 2022. These invite-only conferences aim to connect with clients and stakeholders. For more information, visit movanohealth.com.
FAQ
What is the current stock price of Movano (MOVE)?
What is the market cap of Movano (MOVE)?
What does Movano Inc. do?
What is the Evie Ring?
Has Movano Health conducted any clinical trials?
What recent investments has Movano Health secured?
What is the Evie Med Ring?
How does Movano's technology benefit the healthcare sector?
What partnerships has Movano Health formed?
What are the main features of the Evie Ring?
When was Movano Inc. founded?
Where can I find more information about Movano Health?
